×ÉѯÈÈÏß
18616108315
18616108315
²úÎï·ÖÀà
Product CategoryÏêϸ½éÉÜ
| Æ·ÅÆ | ³¢¾±´Ú±ð-¾±³¢²¹²ú/Àî¼ÇÉúÎï |
|---|
22¸é³Õ1£¨ÈËÇ°ÁÐÏÙ°©Ï¸°û£©ÃèÊö
¡¡¡¡22RV1£¨ÖÐÎÄÃû³Æ£ºÈËÇ°ÁÐÏÙ°©Ï¸°û£©£¬À´Ô´ÓÚÈËÇ°ÁÐÏÙ°©£¬Õý³£µÄϸ°ûÐÎ̬ΪÉÏƤϸ°ûÑù£¬Ìù±ÚÉú³¤¡£
¶©¹ºÐÅÏ¢
²úÎïÃû³Æ | »õºÅ | ¹æ¸ñ |
22RV1 | AX03L731 | T25/1 mL |
ÔËÊ䷽ʽ
³£ÎÂ/¸É±ùÔËÊä¡£
22¸é³Õ1£¨ÈËÇ°ÁÐÏÙ°©Ï¸°û£©Ê¹Ó÷½·¨
ÅàÑø·½·¨
ÅàÑø»ù | RPMI-1640 90%, Fetal Bovine Serum(GIBCO:10099-141)»òºÍÔªÀî¼ÇÌؼ¶Ì¥Å£ÑªÇå (Foetal Bovine Serum)£¨»õºÅ£ºAC03L055£© 10% |
ÅàÑøÌõ¼þ | 37¡æ 5% CO2 |
Ïû»¯Ìõ¼þ | 0.25% (w/v) Trypsin-0.53 mM EDTAÈÜÒº£¬Ïû»¯1-3min£¬¹Û²ìµ½Ï¸°ûÃ÷ÏÔ±äÔ²Óмä϶ʱ¿ÉÖÕÖ¹ |
´«´ú±ÈÀý | 1£º3-1£º6 |
»»ÒºÊ±¼ä | 2-3Ìì»»ÒºÒ»´Î |
¶³´æ·½·¨
¶³´æÒº | 55%ÅàÑø»ù£¬40%FBS, 5% (v/v) DMSO »ò ºÍÔªÀî¼Ç¿ìËÙϸ°û¶³´æÒº£¨ÎÞѪÇå¡¢ÎÞµ°°×£©£¨»õºÅ£ºAC05L033£© |
¶³´æÃÜ¶È | 1-3 ¡Á106 /¹Ü£¬Òºµª±£´æ |
¡¡ ¾ßÌå²Ù×÷·½·¨¼ûϸ°ûʹÓÃ˵Ã÷Êé
×¢ÒâÊÂÏî
±¾²úÎï½öÏÞÓÚ¿ÆѧʵÑéÑо¿Ê¹Ó㬲»µÃÓÃÓÚÁÙ´²Õï¶Ï¡¢ÖÎÁƵÈÁìÓò¡£
µ±ÊÕµ½Ï¸°ûºó£¬Çë×ÐϸÔĶÁϸ°ûʹÓÃ˵Ã÷Ê飬°´¹æ¶¨²Ù×÷²¢¼Ç¼ϸ°û״̬£¨ÅÄÕÕ£©¡£ÎÒ˾Ϊ¿Í»§ÌṩһÖÜÄÚµÄÊÛºó±£ÕÏ£¬Ìض¨Çé¿öÏ¿ÉÃâ·ÑÖØ·¢Ï¸°û¡£
²Î¿¼ÎÄÏ×
Sramkoski RM, et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell. Dev. Biol. Anim. 35: 403-409, 1999. PubMed: 10462204
Knouf EC, et al. Multiple integrated copies and high-level production of the human retrovirus XMRV from 22Rv1 prostate carcinoma cells. J. Virol. 83: 7353-7356, 2009. PubMed: 19403664
Ïà¹Ø²úÎïÍƼö
Ìؼ¶Ì¥Å£ÑªÇå (Foetal Bovine Serum)£¨»õºÅ£ºAC03L055£©
RPMI-1640 medium (º¬L-¹È°±µÄõ£°·)£¨»õºÅ£ºAC01L064£©
±¾²úÎï½öÏÞÓÚ¿ÆѧʵÑéÑо¿Ê¹Ó㬲»µÃÓÃÓÚÁÙ´²Õï¶Ï¡¢ÖÎÁƵÈÁìÓò¡£
²úÎï×Éѯ
΢ÐÅ×Éѯµç»°
΢ÐÅ×Éѯ
¹Ø×¢¹«ÖÚºÅ
µ±Ç°Î»Öãº
